Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Tumor-specific immunotherapy holds the promise of eradicating malignant tumors with exquisite precision without additional toxicity to standard treatments. Via Krishan Maggon 
|
Scoop.it!
Abstract The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC. Via Krishan Maggon
Krishan Maggon 's curator insight,
March 25, 2015 2:38 AM
Preamble to the 2015 SITC immunotherapy biomarkers taskforce
Lisa H Butterfield16*, Mary L Disis2, Bernard A Fox3, Samir N Khleif4 and Francesco M Marincola5 *Corresponding author: Lisa H Butterfield butterfieldl@upmc.edu Author Affiliations 1University of Pittsburgh, Pittsburgh, PA, USA 2University of Washington, Seattle, WA, USA 3Oregon Health and Science University, Portland, OR, USA 4GRU Cancer Center, Georgia Regents University, Augusta, GA, USA 5Sidra Medical and Research Center, Doha, Qatar 6University of Pittsburgh, Hillman Cancer Center, 5117 Centre Avenue, Suite 1.27, Pittsburgh 15213, PA, USA For all author emails, please log on. Journal for Immunotherapy of Cancer 2015, 3:8 doi:10.1186/s40425-015-0052-6 The electronic version of this article is the complete one and can be found online at:http://www.immunotherapyofcancer.org/content/3/1/8 |
Review
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeuticsElias J Sayour12, Luis Sanchez-Perez3, Catherine Flores1 and Duane A Mitchell1*
*Corresponding author: Duane A Mitchellduane.mitchell@neurosurgery.ufl.edu
Author Affiliations
1Department of Neurosurgery, UF Brain Tumor Immunotherapy Program, University of Florida, Gainesville, Fl, USA
2Department of Pathology, Duke University Medical Center, Durham, NC, USA
3Division of Neurosurgery, Department of Surgery, Duke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, NC, USA
For all author emails, please log on.
Journal for Immunotherapy of Cancer 2015, 3:13 doi:10.1186/s40425-015-0058-0